# Cerenome, Inc.: overview CNSY · Nasdaq · CIK 1095981 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cnsy.md) · [Financials](/companies/cnsy/financials.md) · [Filings](/companies/cnsy/filings.md) · [Insiders](/companies/cnsy/insiders.md) Latest reported revenue: [$411.0k](/filings/0001193125-26-352444.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-352444). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,456](/filings/0001193125-25-258596.md) | [1,412 d](/filings/0001193125-26-104258.md) | [1,059](/filings/0001193125-26-226978.md) | [1,390](/filings/0001193125-26-352444.md) | [1,397](/filings/0001193125-25-258596.md) | [1,367 d](/filings/0001193125-26-104258.md) | [1,028](/filings/0001193125-26-226978.md) | [411](/filings/0001193125-26-352444.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(260.9%)](/filings/0001193125-25-258596.md) | [(276.2%) d](/filings/0001193125-26-104258.md) | [(333.9%)](/filings/0001193125-26-226978.md) | [(110.6%)](/filings/0001193125-26-352444.md) | [(320.8%)](/filings/0001193125-25-258596.md) | [(420.0%) d](/filings/0001193125-26-104258.md) | [(692.5%)](/filings/0001193125-26-226978.md) | [(2203.6%)](/filings/0001193125-26-352444.md) | | Net margin | % | [(197.4%)](/filings/0001193125-25-258596.md) | [(276.4%) d](/filings/0001193125-26-104258.md) | [(1643.2%)](/filings/0001193125-26-352444.md) | [370.6%](/filings/0001193125-26-352444.md) | [(316.6%)](/filings/0001193125-25-258596.md) | [(417.9%) d](/filings/0001193125-26-104258.md) | [(675.7%)](/filings/0001193125-26-352444.md) | [(2191.2%)](/filings/0001193125-26-352444.md) | | Diluted EPS | $ per share | [(0.37)](/filings/0001193125-25-258596.md) | not reported | [(29.86)](/filings/0001193125-26-226978.md) | [(0.16)](/filings/0001193125-26-352444.md) | [(0.04)](/filings/0001193125-25-258596.md) | not reported | [(1.05)](/filings/0001193125-26-226978.md) | [(1.31)](/filings/0001193125-26-352444.md) | | Free cash flow | $k | [(3,694) d](/filings/0001193125-25-258596.md) | [(1,222) d](/filings/0001193125-26-104258.md) | [(6,175)](/filings/0001193125-26-226978.md) | [(5,805) d](/filings/0001193125-26-352444.md) | [(2,575) d](/filings/0001193125-25-258596.md) | [(6,287) d](/filings/0001193125-26-104258.md) | [(7,056)](/filings/0001193125-26-226978.md) | [(7,631) d](/filings/0001193125-26-352444.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [4.9](/filings/0000950170-25-047698.md) | [5.8](/filings/0001193125-26-104258.md) | [5.2](/filings/0001193125-26-104258.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(271.1%)](/filings/0000950170-25-047698.md) | [(252.3%)](/filings/0001193125-26-104258.md) | [(293.5%)](/filings/0001193125-26-104258.md) | | Net margin | % | not reported | not reported | [(271.0%)](/filings/0000950170-25-047698.md) | [(222.8%)](/filings/0001193125-26-104258.md) | [(429.4%)](/filings/0001193125-26-104258.md) | | Diluted EPS | $ per share | [(1.11)](/filings/0000950170-23-004099.md) | [(11.58)](/filings/0000950170-24-025851.md) | [(4.24)](/filings/0000950170-25-047698.md) | [(2.34)](/filings/0001193125-26-104258.md) | [(0.29)](/filings/0001193125-26-104258.md) | | Free cash flow | $m | not reported | not reported | [(13.0)](/filings/0000950170-25-047698.md) | [(10.7)](/filings/0001193125-26-104258.md) | [(20.8)](/filings/0001193125-26-104258.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cnsy/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.3m | 304,745 | | New +304,745 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $419.4k | 95,983 | | New +95,983 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $332.9k | 76,155 | | New +76,155 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $161.1k | 36,868 | | New +36,868 | | [Ashton Thomas Private Wealth, LLC](/funds/2019663.md) | 2026-06-30 | $149.9k | 34,306 | | New +34,306 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $111.9k | 25,597 | | New +25,597 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $67.8k | 15,516 | | New +15,516 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $26.9k | 6,156 | | New +6,156 | | [Vanguard Global Advisers, LLC](/funds/1811242.md) | 2026-06-30 | $10.0k | 2,282 | | New +2,282 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $8.7k | 2,000 | | New +2,000 | ## Recent filings [All 1,119 filings](/companies/cnsy/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 11:30 ET | [8-K](/filings/0001193125-26-411259.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-411259 | | 2026-09-10 | 12:01 ET | [8-K](/filings/0001193125-26-387267.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-387267 | | 2026-08-14 | 20:35 ET | [10-Q](/filings/0001193125-26-352444.md) | Quarterly report, period 2026-06-30 | 0001193125-26-352444 | | 2026-08-14 | 20:21 ET | [8-K](/filings/0001193125-26-352346.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-352346 | | 2026-08-04 | 20:30 ET | [8-K](/filings/0001193125-26-332939.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-332939 | | 2026-06-05 | 20:30 ET | [8-K](/filings/0001193125-26-259703.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-259703 | | 2026-05-15 | 20:46 ET | [8-K](/filings/0001193125-26-227059.md) | 5.07 Shareholder vote results | 0001193125-26-227059 | | 2026-05-15 | 20:33 ET | [10-Q](/filings/0001193125-26-226978.md) | Quarterly report, period 2026-03-31 | 0001193125-26-226978 | | 2026-05-15 | 20:13 ET | [8-K](/filings/0001193125-26-226747.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-226747 | | 2026-04-21 | 12:30 ET | [8-K](/filings/0001193125-26-165205.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-165205 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104258.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e32918c3-39f5-434d-a414-caa969d70ace) ## About the filer - CIK: 1095981 - Tickers: CNSY - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.